JP2012131827A5 - - Google Patents

Download PDF

Info

Publication number
JP2012131827A5
JP2012131827A5 JP2012077545A JP2012077545A JP2012131827A5 JP 2012131827 A5 JP2012131827 A5 JP 2012131827A5 JP 2012077545 A JP2012077545 A JP 2012077545A JP 2012077545 A JP2012077545 A JP 2012077545A JP 2012131827 A5 JP2012131827 A5 JP 2012131827A5
Authority
JP
Japan
Prior art keywords
weight
amount
composition
desoxyascomycin
epi
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012077545A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012131827A (ja
JP5599422B2 (ja
Filing date
Publication date
Priority claimed from GB9421612A external-priority patent/GB9421612D0/en
Priority claimed from GB9422306A external-priority patent/GB9422306D0/en
Priority claimed from GBGB9503553.1A external-priority patent/GB9503553D0/en
Application filed filed Critical
Publication of JP2012131827A publication Critical patent/JP2012131827A/ja
Publication of JP2012131827A5 publication Critical patent/JP2012131827A5/ja
Application granted granted Critical
Publication of JP5599422B2 publication Critical patent/JP5599422B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2012077545A 1994-10-26 2012-03-29 医薬組成物 Expired - Lifetime JP5599422B2 (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB9421612.4 1994-10-26
GB9421612A GB9421612D0 (en) 1994-10-26 1994-10-26 Organic compounds
GB9422306.2 1994-11-04
GB9422306A GB9422306D0 (en) 1994-11-04 1994-11-04 Organic compounds
GBGB9503553.1A GB9503553D0 (en) 1995-02-22 1995-02-22 Organic compounds
GB9503553.1 1995-02-22

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2007047216A Division JP2007145860A (ja) 1994-10-26 2007-02-27 医薬組成物

Publications (3)

Publication Number Publication Date
JP2012131827A JP2012131827A (ja) 2012-07-12
JP2012131827A5 true JP2012131827A5 (enExample) 2013-05-30
JP5599422B2 JP5599422B2 (ja) 2014-10-01

Family

ID=27267447

Family Applications (3)

Application Number Title Priority Date Filing Date
JP51431096A Expired - Lifetime JP4155593B2 (ja) 1994-10-26 1995-10-26 医薬組成物
JP2007047216A Withdrawn JP2007145860A (ja) 1994-10-26 2007-02-27 医薬組成物
JP2012077545A Expired - Lifetime JP5599422B2 (ja) 1994-10-26 2012-03-29 医薬組成物

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP51431096A Expired - Lifetime JP4155593B2 (ja) 1994-10-26 1995-10-26 医薬組成物
JP2007047216A Withdrawn JP2007145860A (ja) 1994-10-26 2007-02-27 医薬組成物

Country Status (25)

Country Link
US (1) US6352998B2 (enExample)
EP (2) EP1147766B1 (enExample)
JP (3) JP4155593B2 (enExample)
KR (1) KR100434682B1 (enExample)
CN (2) CN100335063C (enExample)
AT (2) ATE214593T1 (enExample)
AU (1) AU714254B2 (enExample)
BR (1) BR9509530A (enExample)
CA (1) CA2200966C (enExample)
CY (1) CY2211B1 (enExample)
CZ (1) CZ289773B6 (enExample)
DE (3) DE69525957T2 (enExample)
DK (2) DK0786986T3 (enExample)
ES (2) ES2243369T3 (enExample)
FI (2) FI119754B (enExample)
GB (1) GB2308546B (enExample)
HU (1) HU223840B1 (enExample)
MX (1) MX9702699A (enExample)
NO (2) NO316963B1 (enExample)
NZ (2) NZ331824A (enExample)
PL (1) PL184750B1 (enExample)
PT (2) PT1147766E (enExample)
SI (1) SI0786986T1 (enExample)
SK (1) SK284591B6 (enExample)
WO (1) WO1996013249A1 (enExample)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR004480A1 (es) * 1995-04-06 1998-12-16 Amico Derin C D Compuestos de ascomicina que poseen actividad antiinflamatoria, pro cedimiento para prepararlos, uso de dichos compuestos para preparar agentesfarmaceuticos y composiciones farmaceuticas que los incluyen
GB9601120D0 (en) * 1996-01-19 1996-03-20 Sandoz Ltd Organic compounds
CZ267796A3 (cs) * 1996-09-12 1998-04-15 Galena A.S. Léčivé přípravky, zejména pro vnitřní aplikaci, ve formě samomikroemulgujících terapeutických systémů
US6495579B1 (en) * 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
TW450810B (en) * 1997-02-20 2001-08-21 Fujisawa Pharmaceutical Co Macrolides antibiotic pharmaceutical composition for preventing and treating skin diseases
DE19744621A1 (de) * 1997-10-09 1999-04-15 Muehlbauer Ernst Kg Mischung zur Verwendung als Wundverband
GB9723669D0 (en) * 1997-11-07 1998-01-07 Univ Aberdeen Skin penetration enhancing components
DE19802205A1 (de) * 1998-01-22 1999-07-29 Beiersdorf Ag Kosmetische und dermatologische Zubereitungen, enthaltend erhöhte Elektrolytkonzentrationen
ID25908A (id) * 1998-03-06 2000-11-09 Novartis Ag Prakonsentrat-prakonsentrat emulsi yang mengandung siklosporin atau makrolida
TR200003108T2 (tr) * 1998-04-27 2001-02-21 Fujisawa Pharmaceutical Co., Ltd. İlaç kompozisyonları
GB9814640D0 (en) * 1998-07-06 1998-09-02 Fujisawa Pharmaceutical Co New use
GB9826656D0 (en) * 1998-12-03 1999-01-27 Novartis Ag Organic compounds
US20070032853A1 (en) * 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
GB0003932D0 (en) * 2000-02-18 2000-04-12 Novartis Ag Pharmaceutical compositions
EP1842569A3 (de) * 2001-02-16 2010-03-03 Abbott Laboratories Vascular Enterprises Limited Implantate mit FK506
GB0108498D0 (en) * 2001-04-04 2001-05-23 Novartis Ag Organic Compounds
TWI324925B (en) * 2001-08-23 2010-05-21 Novartis Ag Ophthalmic composition
AR038628A1 (es) * 2002-03-04 2005-01-19 Novartis Ag Composicion oftalmica
GB0218996D0 (en) * 2002-08-14 2002-09-25 Novartis Ag Organic compounds
US20060115522A1 (en) * 2003-02-17 2006-06-01 Cipla Ltd Pharmaceutical composition
US20040214753A1 (en) * 2003-03-20 2004-10-28 Britten Nancy Jean Dispersible pharmaceutical composition for treatment of mastitis and otic disorders
GB0307869D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Pharmaceutical composition
GB0307867D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Pharmaceutical composition
GB0307866D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Pharmaceutical composition
JP2007500691A (ja) * 2003-07-31 2007-01-18 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 抗炎症剤の分散性製剤
GB0408070D0 (en) * 2004-04-08 2004-05-12 Novartis Ag Pharmaceutical formulations
CA2556993C (en) * 2004-04-08 2013-05-21 Novartis Ag Pimecrolimus foam composition containing hexylene glycol, optionally oleyl alcohol, dimethylisosorbide and/or medium chain triglycerides
GB0508827D0 (en) * 2005-04-29 2005-06-08 Novartis Ag Cosmeceutical composition
US9205080B2 (en) 2006-11-16 2015-12-08 Transderm, Inc. Methods of treating keratin hyperproliferation disorders using mTOR inhibitors
EP2016935A1 (en) * 2007-07-09 2009-01-21 Intendis GmbH Pharmaceutical composition for topical application of poorly soluble compounds
CN101288643B (zh) * 2008-06-17 2012-11-14 杨喜鸿 含有他克莫司的凝胶剂组合物及其制备方法和药物应用
EP2308468A1 (en) * 2009-10-08 2011-04-13 Novaliq GmbH Novel pharmaceutical composition comprising a macrolide immunosuppressant drug
GB0917817D0 (en) 2009-10-12 2009-11-25 Biotica Tech Ltd Novel compounds and methods for their production
GB0917816D0 (en) 2009-10-12 2009-11-25 Biotica Tech Ltd Novel compounds and methods for their production
EP2366378A1 (en) 2010-03-01 2011-09-21 Dexcel Pharma Technologies Ltd. Sustained-release donepezil formulations
WO2012011192A1 (ja) * 2010-07-23 2012-01-26 マルホ株式会社 タクロリムスを含有する水中油型クリーム状組成物
CN102552253A (zh) * 2012-01-17 2012-07-11 唯美度科技（北京）有限公司 一种祛痘用皮肤外用剂
JP6084579B2 (ja) * 2012-01-25 2017-02-22 マルホ株式会社 タクロリムスを含有する水中油型クリーム状組成物
US10172789B2 (en) 2013-01-24 2019-01-08 Palvella Therapeutics Llc Compositions for transdermal delivery of mTOR inhibitors
MX367121B (es) * 2013-08-02 2019-08-06 Laboratorio Raam De Sahuayo S A De C V Composición sólida estable de inmunosupresores.
DE102013222164A1 (de) * 2013-10-31 2015-04-30 Deb Ip Limited Stabilisierte multiple Emulsionen als Hautschutzprodukt
US10765665B2 (en) 2015-11-24 2020-09-08 Melin Jeffrey Composition comprising combination of rapamycin and an activator of AMP kinase and use thereof for treating diseases
CN105663027B (zh) * 2016-04-01 2018-12-18 中国人民解放军广州军区武汉总医院 西罗莫司外用制剂、其制备方法及用途
CN109069418B (zh) 2016-04-04 2026-03-13 Mc2疗法有限公司 包含他克莫司的局部组合物
WO2018129364A1 (en) 2017-01-06 2018-07-12 Palvella Therapeutics Llc Anhydrous compositions of mtor inhibitors and methods of use
KR101973065B1 (ko) 2017-09-13 2019-04-26 (주)썬테크 풍력 발전기 및 풍력 발전기의 블레이드 팁
EP3542788A1 (en) 2018-03-19 2019-09-25 MC2 Therapeutics Limited Topical composition comprising calcipotriol and betamethasone dipropionate
KR101995905B1 (ko) 2018-03-27 2019-07-04 (주)썬테크 풍력 발전기 및 풍력 발전기의 발전모터
WO2019233722A1 (en) * 2018-06-08 2019-12-12 Almirall, S.A. Pharmaceutical composition comprising tacrolimus
EP3817743A4 (en) 2018-07-02 2022-07-06 Palvella Therapeutics, Inc. ANHYDROUS COMPOSITIONS OF MTOR INHIBITORS AND METHODS OF USE
WO2024213629A1 (en) * 2023-04-11 2024-10-17 Bausch Health Ireland Limited Topical compositions

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4299826A (en) 1979-10-12 1981-11-10 The Procter & Gamble Company Anti-acne composition
US4894366A (en) 1984-12-03 1990-01-16 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
PH26083A (en) 1987-11-09 1992-02-06 Sandoz Ltd 11, 28-dioxa-4-azatricyclo [22.3.1.04.9) octacos-18-ene derivatives and pharmaceutical compositions containing them and method of use thereof
EP0346427B1 (en) 1987-12-09 1995-03-29 FISONS plc Macrocyclic compounds
KR0159766B1 (ko) * 1989-10-16 1998-12-01 후지사와 토모키치로 양모제 조성물
ATE126803T1 (de) * 1989-11-09 1995-09-15 Sandoz Ag Heteroatome enthaltende tricyclische verbindungen.
US5061700A (en) 1989-11-16 1991-10-29 Gordon Jay Dow Glyceryl acetate ointment vehicles
JPH05504956A (ja) 1990-03-12 1993-07-29 藤沢薬品工業株式会社 トリシクロ化合物
JPH05507915A (ja) 1990-06-11 1993-11-11 藤沢薬品工業株式会社 特発性血小板減少性紫斑病およびバセドウ病治療薬製造のためのｆｋ５０６等のマクロライド化合物の用途
MY110418A (en) 1990-07-02 1998-05-30 Novartis Ag Heteroatoms-containing tricyclic compounds.
ES2099112T3 (es) * 1990-09-04 1997-05-16 Fujisawa Pharmaceutical Co Pomadas que contienen un compuesto triciclico.
US5143918A (en) * 1990-10-11 1992-09-01 Merck & Co., Inc. Halomacrolides and derivatives having immunosuppressive activity
PH31204A (en) * 1990-11-02 1998-05-05 Fujisawa Pharmaceutical Co Pharmaceutical composition.
CA2054983A1 (en) * 1990-11-08 1992-05-09 Sotoo Asakura Suspendible composition and process for preparing the same
US5247076A (en) 1991-09-09 1993-09-21 Merck & Co., Inc. Imidazolidyl macrolides having immunosuppressive activity
US5208241A (en) 1991-09-09 1993-05-04 Merck & Co., Inc. N-heteroaryl, n-alkylheteroaryl, n-alkenylheteroaryl and n-alkynylheteroarylmacrolides having immunosuppressive activity
US5252732A (en) 1991-09-09 1993-10-12 Merck & Co., Inc. D-heteroaryl, O-alkylheteroaryl, O-alkenylheteroaryl and O-alkynylheteroarylmacrolides having immunosuppressive activity
HUT66531A (en) 1992-05-07 1994-12-28 Sandoz Ag Heteroatoms-containing tricyclic compounds, pharmaceutical prepns contg. them and process for producing them
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
JPH06183970A (ja) * 1992-12-16 1994-07-05 Fujisawa Pharmaceut Co Ltd 医薬用組成物
MY110603A (en) 1993-05-27 1998-08-29 Novartis Ag Tetrahydropyran derivatives
CH686761A5 (de) * 1993-05-27 1996-06-28 Sandoz Ag Galenische Formulierungen.
WO1995011039A1 (de) 1993-10-22 1995-04-27 Hexal Pharma Gmbh Pharmazeutische zusammensetzung mit cyclosporin a und alpha-tocopherol

Similar Documents

Publication Publication Date Title
JP2008513467A5 (enExample)
CA2894892A1 (en) Boronic acid derivatives and therapeutic uses thereof
JP2014129360A5 (enExample)
CA2894891A1 (en) Boronic acid derivatives and therapeutic uses thereof
MX355174B (es) Formulaciones de uso topico de tetraciclina, preparaciones y usos de las mismas.
EP3939572C0 (en) VEHICLES FOR THE CONTROLLED ADMINISTRATION OF DIFFERENT PHARMACEUTICAL AGENTS
EP2827866A4 (en) PHARMACEUTICAL COMPOSITIONS WITH BENZYL ALCOHOL
JP2012036176A5 (enExample)
BR112015000229A2 (pt) formulações aquosas estáveis de etanercept
BR112014014832A2 (pt) formulação e método de controlar fungos
WO2014108846A3 (en) Soothing cosmetic composition based on salicylic acid
JP2012236016A5 (enExample)
MX2014014590A (es) Microcapsulas que contienen retinoides, su procedimiento de preparacion y composiciones farmaceuticas que los contienen.
JP2013538853A5 (enExample)
EP2643002A4 (en) PHARMACEUTICAL FORMULATIONS WITH CORTICOSTEROIDS FOR TOPICAL ADMINISTRATION
EP2827868A4 (en) PHARMACEUTICAL COMPOSITIONS WITH FATTY ACID ESTERS
BR112016011170A8 (pt) derivados de heteroaril ácido butanoico, seus usos, combinação e composição farmacêutica
AR091039A1 (es) Composiciones farmaceuticas topicas que comprenden terbinafina, uso y metodo de tratamiento
CL2016001148A1 (es) Sistema multiparticulado para la administración oral de drogas, que comprende partículas de microgel que contienen un ingrediente farmacéutico activo, donde las partículas de microgel están dispersas en una composición líquida no acuosa proceso para prepararlo cápsulas que lo comprenden.
PH12015502717A1 (en) Anti-fibrogenic compounds, methods and uses thereof
HK1222337A1 (zh) 用於施加药物活性成分或化妆品活性成分的局部组合物和载体
FR2999086B1 (fr) Composition orale et/ou buccale sous forme de film fin d'un principe actif faiblement soluble, son procede de preparation et son utilisation
EP2987786A4 (en) AMIDOPYRIDINOL DERIVATIVE OR PHARMACEUTICAL, SALT AND PHARMACEUTICAL COMPOSITION THEREFOR AS ACTIVE SUBSTANCE
JP2014062109A5 (enExample)
EP2978428A4 (en) STABLE NANO COMPOSITION WITH EPIRUBICIN, PROCESS FOR THE PRODUCTION THEREOF, THE USE THEREOF AND PHARMACEUTICAL COMPOSITIONS THEREWITH